1. Home
  2. NYC vs CDT Comparison

NYC vs CDT Comparison

Compare NYC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

HOLD

Current Price

$8.35

Market Cap

23.5M

Sector

Finance

ML Signal

HOLD

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$2.21

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYC
CDT
Founded
2013
2019
Country
United States
United States
Employees
N/A
6
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.5M
22.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NYC
CDT
Price
$8.35
$2.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1K
68.8K
Earning Date
04-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
85.28
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.03
$0.37
52 Week High
$16.30
$11.00

Technical Indicators

Market Signals
Indicator
NYC
CDT
Relative Strength Index (RSI) 50.52 43.05
Support Level $8.14 $1.31
Resistance Level $8.88 $2.30
Average True Range (ATR) 0.29 0.40
MACD 0.05 -0.29
Stochastic Oscillator 50.00 1.97

Price Performance

Historical Comparison
NYC
CDT

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Share on Social Networks: